Amarin Stock News

Erste Health Technology Assessment (HTA)-Kostenerstattung in Europa leitet die nächste Phase der Wachstumsstrategie des Unternehmens ein

Traguardo del primo rimborso di Health Technology Assessment (HTA) in Europa e avvio della fase successiva della strategia di crescita dell'Azienda

Supone el primer reembolso por Evaluación de las Tecnologías Sanitarias (ETS) en Europa y el inicio de la siguiente fase de la estrategia de crecimiento de la empresa

Cela marque le premier remboursement de l'évaluation des technologies de la santé (ETS) en Europe et le lancement de la prochaine étape de la stratégie de croissance de la Société

Amarin Corporation <>, the maker of lipid-lowering agent Vascepa, recovered from three back-to-back days of losses after Piper Sandler issued positive remarks on the company’s…

Una nuova sottoanalisi a posteriori del memorabile studio REDUCE-IT, pubblicata sulla rivista Journal of the American Heart Association (JAHA), ha dimostrato che VASCEPA® ha ridotto significativamen

Eine neue Post-hoc-Unteranalyse der wegweisenden REDUCE-IT-Studie, die im Journal of the American Heart Association (JAHA) veröffentlicht wurde, hat gezeigt, dass VASCEPA® das Risiko für kardiovas

Uit een nieuwe posthoc subanalyse van de baanbrekende REDUCE-IT-studie, gepubliceerd in het Journal of the American Heart Association (JAHA), blijkt dat VASCEPA® het risico op cardiovasculair overlij

En un nuevo subanálisis a posteriori del estudio de referencia REDUCE-IT, publicado en el Journal of the American Heart Association (JAHA), se comprobó que VASCEPA® disminuyó de manera significati

Une nouvelle sous-analyse post-hoc de l'étude phare REDUCE-IT, publiée dans le Journal of the American Heart Association (JAHA), a révélé que VASCEPA® a considérablement réduit le risque de d�

A new analysis from Amarin (AMRN) found that Vascepa (icosapent ethyl) significantly lowered the risk of potentially fatal cardiovascular events.

A new post hoc sub-analysis of the landmark REDUCE-IT Study, published in the Journal of the American Heart Association (JAHA), found VASCEPA® significantly reduced the risk of cardiovascular death,

An investigation on behalf of current long term investors in Amarin Corporation plc (NASDAQ:AMRN) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 03/09/2022 -- An investigation was announced for investors in shares of Amarin Corporation plc (NASDAQ: AMRN) concerning potential breaches of fiduciary duties by certain directors and officers of Amarin Corporation plc. Investors who are current long term investors in Amarin Corporation plc (NASDAQ: AMRN) shares, have certain options and should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: AMRN stocks follows a lawsuit filed against Amarin Corporation plc (NASDAQ: AMRN over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: AMRN stocks, concerns whether certain Amarin Corporation plc directors are liable in connection with the allegations made in that lawsuit.

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Cowen 42nd Annual Health Care Conference (Transcript)